Regulatory History Empowers enforcement record spans nearly a decade across both its 503A and 503B operations: 2017 FDA Warning Letter issued after a 2015 inspection found that Empower produced drug products without valid prescriptions for individually identified patients, and that sterile drug products were prepared under insanitary conditions that put patients at risk 2021 FDA Warning Letter issued to the 503B outsourcing facility after a 2020 inspection found that drug products failed to meet the conditions of Section 503B of the FDCA 2024 FDA Form 483 documented fill weight discrepancies in semaglutide vials, inadequate quality control sampling procedures, and deficiencies in aseptic processing areas April 2025 FDA Warning Letter cited drug products intended or expected to be sterile that were prepared, packed, or held under insanitary conditions

In the Sham group, mitochondria were abundant, displaying intact double membranes, well-organized cristae with a typical lamellar morphology, and a uniformly dense matrix with moderate electron density
cAMP-response element binding protein (CREB), a crucial downstream target of PKA, effectively suppresses breast cancer cell proliferation following GLP-1R activation [60, 61]
Age-associated decreased activities of mitochondrial electron transport chain complexes in heart and skeletal muscle: role of L-carnitine
Early application of NAC after intracerebral hemorrhage can reduce neuronal mortality and effectively improve the prognosis of patients 73